Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 6
Submit an article Journal homepage
157
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation

Fumiya Wadaa Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;b Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, JapanORCID Iconhttps://orcid.org/0000-0001-6039-146X
ORCID Icon,
Yoshimitsu Shimomuraa Department of Hematology, Kobe City Medical Center General Hospital, Kobe, JapanCorrespondence[email protected]
,
Kimimori Kamijoa Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
,
Daisuke Yamashitac Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Japan
,
Aya Ohnod Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan
,
Mayuko Himenod Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan
,
Hayato Maruokad Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan
,
Shigeo Harac Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Japan
&
Takayuki Ishikawaa Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan
 show all
Pages 1484-1487 | Received 23 Sep 2021, Accepted 20 Dec 2021, Published online: 19 Jan 2022

References

  • Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633–643.
  • Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426–2433.
  • Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989–1996.
  • Wada F, Shimomura Y, Yabushita T, et al. CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma. Hematol Oncol. 2021;39(4):483–489.
  • Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
  • Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–3459.
  • Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551–561.
  • Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
  • Rosenquist R, Thunberg U, Johnson A, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood. 2000;96(11):367a–367a.
  • Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia. 2002;16(1):30–35.
  • Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood. 2003;102(6):2146–2155.
  • Nipp RD, Volkheimer AD, Davis ED, et al. CD38 variation as a prognostic factor in chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(1):191–194.
  • Alsuwaidan A, Pirruccello E, Jaso J, et al. Bright CD38 expression by flow cytometric analysis is a biomarker for double/triple hit lymphomas with a moderate sensitivity and high specificity. Cytometry B Clin Cytom. 2019;96(5):368–374.
  • Rodig SJ, Vergilio JA, Shahsafaei A, et al. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008;32(1):113–122.
  • Vidal-Crespo A, Matas-Cespedes A, Rodriguez V, et al. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica. 2020;105(4):1032–1041.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.